STOCK TITAN

Bausch + Lomb Corporation - BLCO STOCK NEWS

Welcome to our dedicated page for Bausch + Lomb Corporation news (Ticker: BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb Corporation stock.

Bausch + Lomb Corporation (BLCO) is a globally recognized leader in the field of eye health, offering comprehensive solutions across three primary business segments: vision care, surgical, and ophthalmic pharmaceuticals. With a history spanning over a century, the company has cemented its reputation as a trusted provider of innovative products and services that address a wide range of eye care needs.

Core Business Segments

Vision Care

The vision care segment encompasses two primary categories: contact lenses and ocular health products. Bausch + Lomb holds a significant share of the global contact lens market, offering a diverse range of lenses tailored to different vision correction needs, including daily disposables, extended-wear lenses, and specialty lenses for astigmatism and presbyopia. Its ocular health products include over-the-counter solutions such as Biotrue and Lumify, which cater to dry eye relief, redness reduction, and overall eye health maintenance.

Surgical

The surgical segment focuses on advanced technologies and equipment designed for ophthalmic procedures. This includes a comprehensive suite of intraocular lenses (IOLs), instruments for cataract and vitreoretinal surgeries, and cutting-edge surgical systems. These solutions are widely used by ophthalmologists to improve patient outcomes in complex eye surgeries, reinforcing Bausch + Lomb's role as a key player in the surgical eye care market.

Ophthalmic Pharmaceuticals

Bausch + Lomb's ophthalmic pharmaceuticals segment features a diverse portfolio of prescription medications that address various eye conditions, including glaucoma, inflammation, and retinal diseases. Notable products include treatments such as Xipere, Vyzulta, and Lotemax. With over 100 prescription eye care products, the company offers one of the most extensive pharmaceutical portfolios in the industry, meeting the needs of both patients and healthcare professionals.

Market Position and Competitive Landscape

Bausch + Lomb operates in the highly competitive eye health and medical device industry, where innovation and trust are paramount. Its competitors include prominent players like Alcon and CooperVision, among others. The company's differentiation lies in its extensive product offerings, longstanding reputation, and commitment to advancing eye care through research and development. By addressing a wide spectrum of eye health needs, Bausch + Lomb has positioned itself as a comprehensive provider in the global market.

Challenges and Opportunities

Operating in a regulated industry, Bausch + Lomb faces challenges such as stringent compliance requirements, pricing pressures, and the need for continuous innovation to stay competitive. However, the company also benefits from opportunities in emerging markets, increasing prevalence of eye conditions, and growing demand for advanced surgical solutions and pharmaceutical treatments. Its ability to adapt to market dynamics and invest in cutting-edge technologies underscores its resilience and growth potential.

Commitment to Eye Health

Bausch + Lomb's mission is deeply rooted in improving lives through better vision. Its investments in research and development, coupled with a focus on quality and safety, reflect its dedication to delivering products that enhance eye health worldwide. As a publicly traded company, Bausch + Lomb continues to build on its legacy of innovation and trust, serving the needs of patients, healthcare providers, and partners across the globe.

Rhea-AI Summary

Bausch + Lomb (NYSE/TSX: BLCO) reported Q4 2024 revenue of $1.280 billion, up 9% year-over-year, with an 11% increase on a constant currency basis. The company posted a Q4 GAAP net loss of $3 million.

Full-year 2024 revenue reached $4.791 billion, representing a 16% increase, with growth across all segments. Vision Care revenue grew to $2.739 billion (+8%), Surgical revenue reached $843 million (+10%), and Pharmaceuticals revenue increased to $1.209 billion (+45%).

For 2025, the company projects revenue between $4.950-$5.050 billion, representing 5.5-7.5% constant currency growth, and Adjusted EBITDA of $900-$950 million. The guidance factors in foreign exchange headwinds of -$100M for revenue and -$20M for Adjusted EBITDA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Bausch + Lomb (NYSE/TSX: BLCO) has announced that its exploration of potential privatization with a third-party buyer has concluded without resulting in a transaction. The company had previously disclosed this possibility in December 2024 following a regulatory request. Full separation from Bausch Health Companies Inc. remains the company's objective.

The eye health company continues to operate independently and execute its business strategies. Notably, BLCO raised its 2024 revenue guidance on October 30 and will report its fourth-quarter and full-year 2024 earnings on February 19, along with providing guidance for fiscal year 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.52%
Tags
none
-
Rhea-AI Summary

Bausch + Lomb (NYSE/TSX: BLCO) has scheduled the release of its fourth-quarter and full-year 2024 financial results for Wednesday, February 19, 2025. The global eye health company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update.

The company will make all materials available on their Investor Relations website before the call. Participants can join via webcast or through dial-in numbers for North America (+1-888-506-0062) and International (+1-973-528-0011) using access code 785090. A replay will be available until March 5, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
Rhea-AI Summary

Bausch + Lomb (NYSE/TSX: BLCO), a global leader in eye health, announced the acquisition of Whitecap Biosciences, , enhancing its clinical-stage pipeline. Whitecap is developing two innovative therapies for glaucoma and geographic atrophy (GA). Whitecap Biosciences, founded in 2015, focuses on novel treatments for serious eye diseases, successfully completing Phase 2 trials for WB007 in glaucoma, a potent alpha-2 adrenergic agonist. Further trials are planned for both glaucoma and GA. Glaucoma, a progressive neurodegenerative disease, affects about four million people in the U.S. and is a leading cause of preventable blindness. GA, also known as advanced dry age-related macular degeneration, affects approximately one million people in the U.S. By joining Bausch + Lomb, Whitecap aims to develop its assets into effective treatments to improve visual outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
-
Rhea-AI Summary

Bausch + Lomb (NYSE/TSX: BLCO) has announced the commercial launch of enVista Aspire monofocal and toric intraocular lenses (IOLs) in the European Union following CE Mark approval. The enVista Aspire combines Intermediate Optimized optics for broader depth of focus with the established enVista platform benefits.

The product features include glistening-free optic material and StableFlex Technology for controlled unfolding. The toric version offers treatment for astigmatism during cataract surgery with a +0.90 cylinder design and AccuSet haptic design for rotational stability.

The IOLs are indicated for primary implantation in adult patients for visual correction of aphakia following cataract lens removal, with the toric version specifically addressing corneal astigmatism. The device uses an optical modification of the posterior aspheric surface to create a small continuous increase in IOL power within the central 1.5 mm diameter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
none
-
Rhea-AI Summary

Outcome Capital announces the successful acquisition of Elios Vision by Bausch + Lomb (NYSE/TSX: BLCO). Elios Vision, a developer of minimally invasive glaucoma surgery (MIGS) using excimer laser technology, has created the ELIOS™ procedure, an implant-free treatment designed to reduce intraocular pressure in glaucoma patients while minimizing risks associated with traditional surgeries.

The technology is currently CE-marked and available in the European Union, with FDA approval being sought this year. The procedure can be performed standalone or alongside cataract surgery, offering broader adoption potential due to its relative simplicity compared to implant-based MIGS. The acquisition strengthens Bausch + Lomb's position in the $2.5 billion glaucoma treatment market, addressing a condition that affects over 76 million people globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Bausch + Lomb (NYSE/TSX: BLCO) and Glaucoma Research Foundation (GRF) are launching their second annual 'Faces of Glaucoma' campaign during Glaucoma Awareness Month in January. The initiative aims to raise awareness about glaucoma, the second leading cause of blindness worldwide, by sharing diverse patient stories and educational resources.

The campaign highlights that approximately half of people with glaucoma are unaware they have the condition. As part of the initiative, Bausch + Lomb will match donations up to $20,000 for the fourth consecutive year to support GRF's research toward finding a cure.

The campaign emphasizes that while glaucoma is often associated with older individuals, it can affect anyone regardless of race, age, or gender. Early intervention, including prescription eye drops, can help slow the disease's progression, though there is currently no cure. Detection requires yearly comprehensive dilated eye exams by eye care professionals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
none
-
Rhea-AI Summary

Bausch + Lomb (NYSE/TSX: BLCO) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's leadership team, including Chairman and CEO Brent Saunders, CFO Sam Eldessouky, and Chief Medical Officer and Head of R&D Yehia Hashad, M.D., will deliver a company presentation on Monday, January 13, 2025, at 11:15 a.m. PT (2:15 p.m. ET).

The global eye health company will provide a live webcast of the event, with an audio archive available afterward on their Investor Relations page at http://ir.bausch.com/investors/events-presentations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
conferences
-
Rhea-AI Summary

Bausch + Lomb (NYSE/TSX: BLCO) has confirmed it is exploring a potential sale as one of several options to achieve complete separation from Bausch Health Companies Inc. The company's board of directors has authorized management and advisors to explore this possibility, though no transaction is guaranteed. This statement was issued in response to a request from the Canadian Investment Regulatory Organization (CIRO) due to stock volatility concerns related to market rumors. The company stated it will not provide additional details until further disclosure becomes appropriate or necessary.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.53%
Tags
none
Rhea-AI Summary

Bausch + Lomb (NYSE/TSX: BLCO) has acquired Elios Vision, Inc., developer of the ELIOS™ procedure, the first clinically validated, minimally invasive glaucoma surgery (MIGS) using an excimer laser. The acquisition strengthens BLCO's glaucoma portfolio by introducing a differentiated treatment approach that can be performed alongside cataract surgery.

The ELIOS system offers a tissue-friendly, non-thermal laser-based procedure for glaucoma, which is expected to see a 47% prevalence increase from 2020 to 2040. The technology is currently CE marked and available in the European Union, with FDA approval pending. Over 19% of cataract surgery patients also have glaucoma or ocular hypertension, presenting an opportunity for concurrent treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.06%
Tags

FAQ

What is the current stock price of Bausch + Lomb Corporation (BLCO)?

The current stock price of Bausch + Lomb Corporation (BLCO) is $16 as of February 28, 2025.

What is the market cap of Bausch + Lomb Corporation (BLCO)?

The market cap of Bausch + Lomb Corporation (BLCO) is approximately 5.6B.

What does Bausch + Lomb Corporation specialize in?

Bausch + Lomb specializes in vision care, surgical solutions, and ophthalmic pharmaceuticals, offering a wide range of eye health products and services.

What are the main business segments of Bausch + Lomb?

The company operates in three main segments: vision care (contact lenses and ocular health products), surgical (intraocular lenses and surgical equipment), and ophthalmic pharmaceuticals (prescription eye medications).

How does Bausch + Lomb differentiate itself from competitors?

Bausch + Lomb differentiates itself through its extensive product portfolio, longstanding reputation in the industry, and commitment to innovation in eye health solutions.

What challenges does Bausch + Lomb face in its industry?

Challenges include regulatory compliance, pricing pressures, competition from established and emerging players, and the need for continuous innovation to meet market demands.

Who are Bausch + Lomb's key competitors?

Key competitors include companies like Alcon, CooperVision, and other major players in the vision care and ophthalmology sectors.

What is Bausch + Lomb's role in the surgical eye care market?

Bausch + Lomb provides advanced surgical solutions, including intraocular lenses, cataract and vitreoretinal surgical equipment, and instruments, catering to ophthalmologists worldwide.

What makes Bausch + Lomb's pharmaceutical portfolio unique?

With over 100 prescription eye care products, Bausch + Lomb offers one of the most extensive ophthalmic pharmaceutical portfolios, addressing conditions like glaucoma, inflammation, and retinal diseases.

How does Bausch + Lomb generate revenue?

Revenue is generated through direct sales of vision care products, partnerships with healthcare providers for surgical solutions, and sales of prescription medications in the ophthalmic pharmaceuticals segment.

What is Bausch + Lomb's commitment to eye health?

Bausch + Lomb is committed to improving lives through better vision by investing in research, ensuring product quality, and addressing a wide range of eye health needs globally.

What opportunities exist for Bausch + Lomb in the market?

Opportunities include expanding into emerging markets, addressing the increasing prevalence of eye conditions, and meeting growing demand for advanced surgical and pharmaceutical solutions.
Bausch + Lomb Corporation

NYSE:BLCO

BLCO Rankings

BLCO Stock Data

5.57B
40.66M
88.44%
11.12%
0.36%
Medical Instruments & Supplies
Ophthalmic Goods
Link
Canada
VAUGHAN